JP2022539152A5 - - Google Patents

Info

Publication number
JP2022539152A5
JP2022539152A5 JP2021577411A JP2021577411A JP2022539152A5 JP 2022539152 A5 JP2022539152 A5 JP 2022539152A5 JP 2021577411 A JP2021577411 A JP 2021577411A JP 2021577411 A JP2021577411 A JP 2021577411A JP 2022539152 A5 JP2022539152 A5 JP 2022539152A5
Authority
JP
Japan
Prior art keywords
disease
parkinson
pharmaceutical composition
disorders
cognitive impairment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021577411A
Other languages
English (en)
Japanese (ja)
Other versions
JP7510444B2 (ja
JP2022539152A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/068183 external-priority patent/WO2021001288A1/en
Publication of JP2022539152A publication Critical patent/JP2022539152A/ja
Publication of JP2022539152A5 publication Critical patent/JP2022539152A5/ja
Application granted granted Critical
Publication of JP7510444B2 publication Critical patent/JP7510444B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021577411A 2019-07-01 2020-06-29 Ｄ１ポジティブアロステリックモジュレーターとしての置換テトラヒドロイソキノリン誘導体 Active JP7510444B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19183643.6 2019-07-01
EP19183643 2019-07-01
PCT/EP2020/068183 WO2021001288A1 (en) 2019-07-01 2020-06-29 A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator

Publications (3)

Publication Number Publication Date
JP2022539152A JP2022539152A (ja) 2022-09-07
JP2022539152A5 true JP2022539152A5 (enExample) 2023-06-30
JP7510444B2 JP7510444B2 (ja) 2024-07-03

Family

ID=67137843

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021577411A Active JP7510444B2 (ja) 2019-07-01 2020-06-29 Ｄ１ポジティブアロステリックモジュレーターとしての置換テトラヒドロイソキノリン誘導体

Country Status (23)

Country Link
US (1) US12643877B2 (enExample)
EP (1) EP3993794A1 (enExample)
JP (1) JP7510444B2 (enExample)
KR (1) KR20220029686A (enExample)
CN (2) CN117700395A (enExample)
AR (1) AR119318A1 (enExample)
AU (1) AU2020299953B2 (enExample)
BR (1) BR112021022378A2 (enExample)
CA (1) CA3139571A1 (enExample)
CL (1) CL2021002946A1 (enExample)
CO (1) CO2021018155A2 (enExample)
EC (1) ECSP21093559A (enExample)
IL (2) IL319939A (enExample)
MA (1) MA56440A (enExample)
MX (2) MX2021015873A (enExample)
MY (1) MY210361A (enExample)
PE (1) PE20221020A1 (enExample)
PH (1) PH12021552825A1 (enExample)
SA (1) SA521431279B1 (enExample)
SG (1) SG11202112537YA (enExample)
TW (1) TWI875776B (enExample)
WO (1) WO2021001288A1 (enExample)
ZA (1) ZA202109193B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020131671A1 (en) 2018-12-18 2020-06-25 Eli Lilly And Company Dose regimens for use of ly3154207 in the treatment of dopaminergic cns disorders
EP4200280B1 (en) 2020-10-07 2024-02-21 Eli Lilly And Company Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1 receptor positive allosteric modulators
SI4263517T1 (sl) 2020-12-18 2025-01-31 UCB Biopharma SRL Substituiran tetrahidroizokinolinski derivat kot pozitivni alosterični modulator d1
CN116685308A (zh) 2020-12-18 2023-09-01 Ucb生物制药有限责任公司 无定形固体分散体
ES3004257T3 (en) 2020-12-18 2025-03-12 UCB Biopharma SRL Prodrugs of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]ethanone
CN117337173A (zh) * 2021-03-09 2024-01-02 伊莱利利公司 美维达林和其他d1正向别构调节剂用于减缓帕金森氏病进展的用途
WO2026022198A1 (en) 2024-07-25 2026-01-29 UCB Biopharma SRL Process for the preparation of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1 s,3 r)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1 h-isoquinolin-2-yl]ethanone monohydrate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010520217A (ja) * 2007-03-01 2010-06-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンｈ３受容体のモジュレーターとしてのテトラヒドロイソキノリン化合物
KR101284796B1 (ko) 2011-10-05 2013-07-10 (주)포인트엔지니어링 캔 패지키 타입의 광 디바이스 제조 방법 및 이에 의해 제조된 광 디바이스
US9278960B2 (en) 2011-11-03 2016-03-08 Merck Sharp & Dohme Corp. Quinoline carboxamide and quinoline carbonitrile derivatives as mGluR2-negative allosteric modulators, compositions, and their use
JO3316B1 (ar) 2013-05-30 2019-03-13 Lilly Co Eli مركبات 3، 4-داي هيدرو أيزو كوينولين -2(1h)-يل
EA035544B1 (ru) 2014-10-08 2020-07-03 Юсб Байофарма Спрл Производные тетрагидроизохинолина
CN108884050B (zh) * 2016-04-13 2022-07-05 Ucb生物制药私人有限公司 四氢异喹啉衍生物
TWI725408B (zh) 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑

Similar Documents

Publication Publication Date Title
AU2019213454B2 (en) 7,8-dihydoxyflavone and 7,8-substituted flavone derivatives, compositions, and methods related thereto
ES2261234T3 (es) Metabolitos de bupropion y metodos de sintesis y uso.
JP2019059760A5 (enExample)
JP2022191257A5 (enExample)
JP2014517050A5 (enExample)
JP2009511568A5 (enExample)
JP2002501025A5 (enExample)
JP2012530779A5 (enExample)
JP2022519744A5 (enExample)
JP2013516488A (ja) 炭酸脱水酵素阻害薬およびさらなる活性剤の組み合わせによる閉塞型睡眠時無呼吸症候群の治療
RS63647B1 (sr) Postupci za lečenje poremećaja abnormalnih nevoljnih pokreta
JP2022537994A5 (enExample)
JP2005508872A5 (enExample)
JP2010513250A5 (enExample)
JP2001523716A5 (enExample)
JPWO2021153665A5 (enExample)
CO6290669A2 (es) Usos terapeuticos de compuestos que tiene afinidad con el transportador de serotonina los receptores de serotonina y transportador de noraadrenalina
JP2019535715A5 (enExample)
JP2018530612A5 (enExample)
JP2024511053A5 (enExample)
FI4263517T3 (fi) Substituoitu tetrahydroisokinoliinijohdannainen d1-positiivisena allosteerisenä modulaattorina
RU2022101512A (ru) Замещенное производное тетрагидроизохинолина, как позитивный аллостерический модулятор d1
TH2101008237A (th) อนุพันธ์เตตระไฮโดรไอโซควิโนลีนที่แทนที่ในฐานะเป็นสารดัดแปลงอัลโลสเตอริกด้านบวกของ d1
RU2022101513A (ru) Замещенное производное тетрагидроизохинолина как позитивный аллостерический модулятор d1
JP2009501205A (ja) 精神病治療用組成物